Ocular absorption behavior of palmitoyl tilisolol, an amphiphilic prodrug of tilisolol, for ocular drug delivery

Kawakami, Shigeru; Nishida, Koyo; Mukai, Takahiro; Yamamura, Kenzo; Kobayashi, Kazuo; Sakaeda, Toshiyuki; Nakamura, Junzo; Nakashima, Makoto; Sasaki, Hidetada

doi:10.1002/jps.1162

Cited by 12 publications

(6 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our previous study, O-palmitoyl tilisolol was converted to tilisolol even in 40% ethanol of PBS, and its half life was 66.6Ϯ 3.4 min. 10) This result suggested that chemical catalysis contributes to the conversion of O-palmitoyl tilisolol to tilisolol. In contrast, O-palmitoyl tilisolol was gradually degraded in various tissue homogenates (Figs.…”

Section: Resultsmentioning

confidence: 96%

See 1 more Smart Citation

Biodistribution and Pharmacokinetics of O-Palmitoyl Tilisolol, a Lipophilic Prodrug of Tilisolol, after Intravenous Administration in Rats.

Kawakami

Ohshima

Hirayama

et al. 2002

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 96%

“…9,10) In the present study, we evaluated the biodistribution and pharmacokinetics after intravenous administration of O-palmitoyl tilisolol in rats. Tilisolol, which is a b-blocker, was used as a model drug because of its easy detection with fluorescence.…”

mentioning

confidence: 99%

Biodistribution and Pharmacokinetics of O-Palmitoyl Tilisolol, a Lipophilic Prodrug of Tilisolol, after Intravenous Administration in Rats.

Kawakami

Ohshima

Hirayama

et al. 2002

Biological & Pharmaceutical Bulletin

Self Cite

View full text Add to dashboard Cite

“…After intravitreal injection of O-palmitoyl tilisolol liposomes the tilisolol concentration at 24 and 48 h was significantly higher compared with the concentration of tilisolol after injection of tilisolol liposomes. O-Palmitoyl tilisolol formulated the micellar solution because of its amphiphilic properties (Kawakami et al 2001). Previously, we reported that the O-palmitoyl tilisolol micellar solution enhanced retention in the tear fluid after topical administration.…”

Section: Resultsmentioning

confidence: 99%

Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes

Kawakami

Yamamura

Mukai

et al. 2001

Journal of Pharmacy and Pharmacology

Self Cite

View full text Add to dashboard Cite

To improve the retention time of tilisolol in the precorneal area or vitreous body, we prepared liposomes incorporating the O-palmitoyl prodrug of tilisolol. O-Palmitoyl tilisolol was completely incorporated in the liposomes. After topical administration of O-palmitoyl tilisolol liposomes to the rabbit eye, O-palmitoyl tilisolol rapidly disappeared from the tear fluid. The inclusion of 2% carmellose sodium slightly prolonged the retention of O-palmitoyl tilisolol in the tear fluid. After intravitreal injection of O-palmitoyl tilisolol liposomes, there was a relatively prolonged retention of O-palmitoyl tilisolol in the vitreous body. At 24 and 48 h after intravitreal injection of O-palmitoyl tilisolol liposomes, the tilisolol concentration in the vitreous body was significantly higher compared with the concentration after intravitreal injection of tilisolol liposomes.

show abstract

“…Alkyl, O-butyryl and O-palmitoyl ester prodrugs have been reported for tilisolol (30) with the aim of enhancing lipophilicity and diacetyl nadolol (31), a prodrug of nadolol was found to be 20 times more lipophilic than the parent drug [61][62].…”

Section: Prodrugs Of -Blockers For Ocular Deliverymentioning

confidence: 99%

Prodrug Strategies for Antihypertensives

Dhaneshwar¹,

Sharma²,

Patel³

et al. 2011

CTMC

View full text Add to dashboard Cite

There is a great emphasis on research to discover methods aimed at enhancing the efficacy of drugs and reducing their toxicity and unwanted side effects. Prodrugs are biologically inactive compounds that are converted to actual drug molecule, through biotransformation, that combine with the receptors to produce the biological action. Prodrugs can thus be considered as drugs containing specialized nontoxic protective groups utilized in a transient manner to alter or eliminate the undesirable properties of the parent drug molecule. Hypertension is one of the leading risk factors for cardiovascular disease and represents a major health and economic burden. Most of the drugs for cardiovascular diseases have low oral bioavailability, short duration of action, first pass metabolism and variable lipohilicities. Out of the need to overcome these limitations, various prodrugs have been designed for antihypertensive agents. This review extensively focuses on various strategies used for design and development of prodrugs for the various classes of antihypertensives, emphasizing on the details regarding the need for prodrug synthesis for each class, structure, type of modification and goal achieved. It also provides an insight into the major advances in the field of antihypertensive prodrug research.

show abstract

Ocular absorption behavior of palmitoyl tilisolol, an amphiphilic prodrug of tilisolol, for ocular drug delivery

Cited by 12 publications

References 17 publications

Biodistribution and Pharmacokinetics of O-Palmitoyl Tilisolol, a Lipophilic Prodrug of Tilisolol, after Intravenous Administration in Rats.

Biodistribution and Pharmacokinetics of O-Palmitoyl Tilisolol, a Lipophilic Prodrug of Tilisolol, after Intravenous Administration in Rats.

Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes

Prodrug Strategies for Antihypertensives

Contact Info

Product

Resources

About